Spinal Cord Injury News and Research

RSS

A spinal cord injury usually begins with a sudden, traumatic blow to the spine that fractures or dislocates vertebrae. The damage begins at the moment of injury when displaced bone fragments, disc material, or ligaments bruise or tear into spinal cord tissue. Most injuries to the spinal cord don't completely sever it. Instead, an injury is more likely to cause fractures and compression of the vertebrae, which then crush and destroy the axons, extensions of nerve cells that carry signals up and down the spinal cord between the brain and the rest of the body. An injury to the spinal cord can damage a few, many, or almost all of these axons. Some injuries will allow almost complete recovery. Others will result in complete paralysis.

Allergan receives positive opinion from Irish Medicines Board for BOTOX

Allergan is pleased to announce that BOTOX has received a positive opinion from the Irish Medicines Board for the management of urinary incontinence in adults with neurogenic detrusor overactivity (NDO) resulting from neurogenic bladder due to stable sub-cervical spinal cord injury, or multiple sclerosis.

8 Aug 2011

Roadmap to overcome obstacles for using induced pluripotent stem cells

The possibility of developing stem cells from a patient's own skin and using them to treat conditions as diverse as Parkinson's disease, Alzheimer's disease and cancer has generated tremendous excitement in the stem cell research community in recent years. Such therapies would avoid the controversial need for using stem cells derived from human embryos, and in theory, also bypass immunological problems inherent in using cells from one person to treat another.

5 Aug 2011

NSF awards WSU researcher CAREER grant to develop neural implants

Neural implants have the potential to treat disorders and diseases that typically require long-term treatment, such as blindness, deafness, epilepsy, spinal cord injury, and Alzheimer's and Parkinson's. However, implantable devices have been problematic in clinical applications because of bodily reactions that limit device functioning time.

4 Aug 2011

Noninvasive brain computer interface could turn thoughts into motion

"Brain cap" technology being developed at the University of Maryland allows users to turn their thoughts into motion. Associate Professor of Kinesiology José 'Pepe' L. Contreras-Vidal and his team have created a non-invasive, sensor-lined cap with neural interface software that soon could be used to control computers, robotic prosthetic limbs, motorized wheelchairs and even digital avatars.

28 Jul 2011

Underwater-treadmill improves mobility following spinal-cord injury

The result of research often is shown in hard and fast metrics. For Janette Rodgers, the only metric she cares about is that her wheelchair, once her prison day in and day out, now sits empty 90 percent of the time— in large part because of the hours she spent in 270 gallons of water.

27 Jul 2011

Children and adults with social withdrawal due to Fragile X may benefit from STX209

Children and adults with social withdrawal due to Fragile X syndrome, the most common cause of inherited intellectual disability and the most common known single gene cause of autism, may benefit from an experimental drug under study by pediatric neurologists at Rush Children's Hospital at Rush University Medical Center.

21 Jul 2011

Research: Substance P appears to trigger formation of extraskeletal bone

For hundreds of thousands of people, injuring a muscle through an accident like falling off a bike or having surgery can result in a strange and serious complication. Their muscles start growing bones.

21 Jul 2011

Neuralstem receives U.S. patent allowance for three new neurogenic compounds

Neuralstem, Inc. announced that it has received notice of allowance for U.S. Patent Applications 12/939,897 and 12/939,914 entitled: "Compositions to Effect Neuronal Growth."

15 Jul 2011

Article describes predictors of post-TBI psychiatric disorders

A history of psychiatric illness such as depression or anxiety before a traumatic brain injury (TBI), together with other risk factors, are strongly predictive of post-TBI psychiatric disorders, according to an article published in Journal of Neurotrauma, a peer-reviewed journal published by Mary Ann Liebert, Inc.

13 Jul 2011

Scientists discover way to separate neural wheat from the chaff

University of Florida scientists have discovered a way to separate the neural wheat from the chaff during the process of generating brain cells for potential patient therapies.

8 Jul 2011

InVivo files biopolymer scaffold IDE with FDA to initiate spinal cord injury clinical trial

InVivo Therapeutics today announced that the Company has submitted an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) for a proprietary biopolymer scaffolding device to protect and support spinal tissue and prevent secondary injury, including inflammation and glial scarring, following traumatic spinal cord injury.

8 Jul 2011

Experiment to protect astronauts from bone loss during space travel

Astronauts lose a significant amount of bone mass during space travel and with long duration flights there is concern that this bone loss could lead to an increased risk of fractures.

7 Jul 2011

Patients should be allowed to participate in planning their rehabilitation

Results from an MPH thesis show that patients want to participate in planning their own rehabilitation, together with therapists and clinicians. This ensures them control and overview during their rehabilitation process.

4 Jul 2011

FamilyCord launches advanced cord tissue stem cell processing and storage

FamilyCord, one of the nation's leading cord blood banks, today announced their latest contribution to the advancement of the umbilical cord blood and tissue storage industry: CordTissuePlus.

29 Jun 2011

Acorda to move corporate headquarters to Ardsley Park life science campus

Acorda Therapeutics, Inc. today announced that it plans to relocate its corporate headquarters to the Ardsley Park life science campus in Ardsley, New York, which was acquired by BioMed Realty Trust, Inc..

27 Jun 2011

ABA honors Acorda Therapeutics president with 2011 Stevie Award

Acorda Therapeutics, Inc. announced that Ron Cohen, M.D., President and CEO of Acorda Therapeutics, was awarded the 2011 Stevie Award for Executive of the Year in the Health Products & Services category at the 9th Annual American Business Awards (ABA) ceremony held on June 20, 2011.

24 Jun 2011

Pfizer Lyrica Phase 3 study on Central Neuropathic Pain meets primary endpoint

Pfizer Inc. announced today that top-line results for Lyrica Study A0081107 - Central Neuropathic Pain Following Spinal Cord Injury - demonstrated that the study met its primary endpoint: positive efficacy in reducing Central Neuropathic Pain following Spinal Cord Injury with Lyrica compared to placebo.

22 Jun 2011

Concert to advance CTP-499, C-21191 into Phase 2 trials for diabetic nephropathy and spasticity

Concert Pharmaceuticals, Inc. announced today the advancement of two programs from its DCE Platform. CTP-499 is progressing into Phase 2 clinical trials for diabetic nephropathy and C-21191 has been selected as a lead candidate for spasticity.

20 Jun 2011

Study: Abdominal debrancing with aortic stent grafts linked to high early mortality

The clinical data from 167 patients who underwent abdominal debrancing combined with aortic stent grafts (ADSG) at 12 centers in North America from1999-2010 were released today at the 65th Vascular Annual Meeting® presented by the Society for Vascular Surgery.

20 Jun 2011

Article reports on bright future and enormous need for stem cell therapeutics

An article in the current issue of Technology & Innovation, Proceedings of the National Academy of Inventors - reports on the bright future and enormous need for stem cell therapeutics that may offer hope for those suffering from debilitating and deadly diseases.

9 Jun 2011